Hypothesis

Chronic mechanical stress in aging tissues promotes phosphorylation of BAG3 at specific serine residues, which decreases its affinity for Hsp70 while increasing its interaction with the mitochondrial outer‑membrane protein FIS1. This shift redirects the BAG3‑CASA machinery toward selective mitophagy, sequestering dynein‑mediated transport and ubiquitin‑chain formation away from cytosolic misfolded proteins. Consequently, despite elevated BAG3 levels, cytosolic proteostasis declines and protein aggregates accumulate, whereas mitochondrial quality control is paradoxically enhanced until mitophagy capacity is exhausted.

Mechanistic Basis

BAG3 normally binds Hsp70’s nucleotide‑binding domain to stimulate ATP hydrolysis, facilitating client ubiquitination by CHIP and handoff to HSPB8‑dynein complexes 2. Phosphorylation of BAG3 (e.g., at Ser^209 or Ser^236) has been shown to alter Hsp70 binding in related co‑chaperones 3. Mechanical strain activates kinases such as ERK1/2 and p38MAPK, which can phosphorylate BAG3 in vitro 4. We propose that phospho‑BAG3 exhibits a conformational change that reduces its Hsp70 ATPase‑stimulating activity but exposes a LIR‑like motif that engages FIS1, recruiting the CASA complex to damaged mitochondria. This creates substrate competition: phospho‑BAG3‑dependent mitophagy consumes dynein and ubiquitin pools, limiting CASA flux for cytosolic clients 6.

Testable Predictions

1. In aged mouse cardiac tissue, phospho‑specific BAG3 levels will correlate with increased colocalization of BAG3 with mitochondrial markers (TOM20, FIS1) and decreased colocalization with cytosolic Hsp70‑client complexes.
2. Inhibiting ERK/p38 MAPK phosphorylation of BAG3 (using selective kinase inhibitors or BAG3 S209A/S236A mutants) will restore cytosolic CASA activity, reduce ubiquitin‑positive aggregates, and impair stress‑induced mitophagy.
3. Overexpressing phospho‑mimetic BAG3 (S209D/S236D) in young cardiomyocytes will shift CASA toward mitochondria, increase mitophagy flux (mt‑Keima assay), and accelerate accumulation of cytosolic aggregates despite higher total BAG3.
4. Rescue of cytosolic proteostasis by enhancing dynein availability (overexpressing dynactin subunit p150^Glued) will alleviate aggregate buildup in phospho‑BAG3‑expressing cells without affecting mitochondrial clearance.

Experimental Design

• Sample: Primary murine cardiomyocytes and heart tissue from young (3 mo) and aged (24 mo) mice.
• Interventions: Treat cells with cyclic stretch (10 % elongation, 1 Hz) ± ERK inhibitor (SCH772984) or p38 inhibitor (SB203580); transduce with AAV‑BAG3 WT, S209A/S236A, or S209D/S236D.
• Readouts:
  • Proximity ligation assay (PLA) for BAG3‑Hsp70 vs. BAG3‑FIS1 interactions.
  • Western blot for phospho‑BAG3 (custom pSer antibodies).
  • Fluorescence reporters: cytosolic mCherry‑CL1 (proteasome‑independent degradation) and mt‑Keima (mitophagy).
  • Aggregate load measured by filter‑trap assay and immunofluorescence for p62.
  • Seahorse analysis for mitochondrial respiration.
• Controls: Non‑stretched cells, kinase‑dead BAG3 mutants, and lysosome inhibition (bafilomycin A1) to confirm flux.

Expected Outcomes

If the hypothesis holds, mechanical stretch will increase phospho‑BAG3, decrease BAG3‑Hsp70 PLA signal, and increase BAG3‑FIS1 PLA signal. Kinase inhibition or non‑phosphorylatable BAG3 will reverse these shifts, improve cytosolic reporter degradation, and reduce aggregates. Phospho‑mimetic BAG3 will produce the opposite phenotype: enhanced mt‑Keima signaling, reduced cytosolic reporter turnover, and increased aggregate formation that is alleviated by dynein overexpression. Failure to observe these patterns would falsify the proposed phosphorylation‑driven rerouting of CASA.

Implications

This mechanism explains the paradox of rising BAG3 but declining cytosolic proteostasis in aging: BAG3 is diverted to a competing quality‑control pathway under persistent mechanical load. Therapeutically, modulating BAG3 phosphorylation or boosting dynein capacity could rebalance CASA substrate allocation, alleviating both protein aggregation and mitochondrial dysfunction in age‑related cardiomyopathies and skeletal myopathies.